RecruitingPhase 2NCT07445919

A Clinical Study to Evaluate SM17 for Atopic Dermatitis

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Clinical Study to Evaluate the Efficacy and Safety of SM17 Monoclonal Antibody Injection (Subcutaneous Injection) in Participants With Moderate to Severe Atopic Dermatitis

Sponsor

SinoMab BioScience Ltd

Enrollment

200 participants

Start Date

Mar 31, 2026

Study Type

INTERVENTIONAL

Conditions

Atopic Dermatitis

Summary

This trial is a phase 2, randomized, double-Blind, placebo-Controlled, dose-finding clinical study conducted in participants with moderate-to-severe atopic dermatitis. The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics , and pharmacodynamics of SM17 (subcutaneous injection) in participants with moderate to severe atopic dermatitis.

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called SM17 for subcutaneous injection and a drug called SM17 placebo for subcutaneous injection for people with atopic dermatitis. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALSM17 for subcutaneous injection

SM17 monoclonal antibody for subcutaneous infusion use

DRUGSM17 placebo for subcutaneous injection

placebo to be compared with SM17, excipient solution of SM17 monoclonal antibody without protein

Locations(1)

Peking University People's Hospital

Beijing, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07445919

Related Trials

Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis

NCT072629831 location

Studies of Skin Microbes in Healthy People and in People With Skin Conditions

NCT006058781 location

Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis

NCT0639791116 locations

Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases

NCT065994111 location

Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares

NCT076458204 locations